Hormone replacement therapy in the prevention and treatment of atherosclerosis

Mosca, Lori

doi:10.1007/s11883-000-0062-8

Cited by 7 publications

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, because of possible serious flaws in the study, a protective benefit of HRT for secondary CVD prevention cannot be ruled out.” Some articles were ghostwritten (see Table S1). For example, a 2000 article authored by Mosca [51] states, “Remarkable consistency among epidemiologic studies supports a cardioprotective role of ERT.”…”

Section: Messagingmentioning

confidence: 99%

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”

Fugh‐Berman

2010

PLoS Med

124

View full text Add to dashboard Cite

show abstract

Section: Messagingmentioning

confidence: 99%

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”

Fugh‐Berman

2010

PLoS Med

124

View full text Add to dashboard Cite

show abstract

“…HDL-C participates in transferring and eliminating lipid so as to protect the cardiovascular system. It has been reported that the use of estrogen in postmenopausal women could decrease the levels of TC and LDL-C and increase those of HDL-C and TG (Mosca, 2000;Lobo et al, 2001). The present study demonstrated that the levels of TG and TC decreased significantly after administration of Herba Epimedii water extract, although LDL-C and HDL-C did not change significantly.…”

Section: Discussionmentioning

confidence: 99%

Herba Epimedii water extract elevates estrogen level and improves lipid metabolism in postmenopausal women

Yan

Liu

et al. 2008

Phytotherapy Research

View full text Add to dashboard Cite

Hormone replacement therapy (HRT) can ameliorate lipid metabolism after menopause, but it is not suitable for long-term use because of serious side effects. Herba Epimedii is a widely used herbal medicine in many Asian countries, it potentially treats menopausal syndrome and its complications with few side effects and good curative effects. The study aimed to evaluate the effects of Herba Epimedii water extract on blood lipid and sex hormone levels. Ninety subjects were randomly divided into two groups: a trial group which received Herba Epimedii water extract and a control group which was administered an equal amount of water placebo. At the baseline and after 6 months of medication, serum estradiol (E(2)), progesterone (P), testosterone (T), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) concentrations were measured. The results indicated that Herba Epimedii water extract decreased the TC and TG levels (p < 0.01). Furthermore, Herba Epimedii water extract significantly increased the serum level of E(2) (p < 0.01) compared with the pre-treatment level. In conclusion, Herba Epimedii water extract produces its beneficial actions in postmenopausal women.

show abstract

“…CHD is a major cause of mobility and mortality in women,89 and the incidence of CHD increases after menopause 81011. Previous observational studies have suggested that there are long-term benefits of menopausal hormone therapy (MHT) for reducing the risk1213 or mortality141516 associated with CHD. Recently, a timing hypothesis has been raised.…”

Section: Introductionmentioning

confidence: 99%

The Effects of Menopausal Hormone Therapy on Serum Level of C-reactive Protein in Postmenopausal Korean Women

et al. 2019

View full text Add to dashboard Cite

Objectives Inflammation is a major mechanism underlying coronary heart disease (CHD) and C-reactive protein (CRP) is a marker of inflammation. When administered soon after menopause, menopausal hormone therapy (MHT) prevents CHD. This study was conducted to examine the impact of estrogen by administration route on CRP in postmenopausal Korean women using micronized progesterone (MP4) for endometrial protection. Methods This retrospective cohort study included 129 healthy women without CHD risk factors. Eighty-nine women took oral estrogen (conjugated equine estrogen, 0.625 mg/day or equivalent), and 40 women applied a 1.5-mg/day 0.1% percutaneous estradiol gel. MP4 was added in 82 women with an intact uterus. The CRP level was measured at baseline and three and six months after initiation of MHT. Results The baseline characteristics were comparable between the MHT groups except current age and age at menopause. After controlling for age, menopausal age, body mass index, and basal CRP, no significant change in CRP was observed in the oral estrogen group (n = 29). Follow-up CRP levels were also similar to the baseline in the percutaneous estrogen group (n = 18). However, three-month CRP was significantly lower than six-month CRP, and there was a significant time trend within the percutaneous estrogen group. However, the group difference did not reach statistical significance. CRP also did not differ by addition of MP4 in either group. Conclusions In postmenopausal Korean women, no change in CRP was observed with oral estrogen, while percutaneous estrogen might decrease CRP. The estrogenic impacts were not influenced by adding MP4.

show abstract

Hormone replacement therapy in the prevention and treatment of atherosclerosis

Cited by 7 publications

References 82 publications

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”

Herba Epimedii water extract elevates estrogen level and improves lipid metabolism in postmenopausal women

The Effects of Menopausal Hormone Therapy on Serum Level of C-reactive Protein in Postmenopausal Korean Women

Contact Info

Product

Resources

About